BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...Seattle Genetics Inc. (NASDAQ:SGEN) FDA grants accelerated approval to Polivy polatuzumab vedotin-piiq in combination with Treanda...
BioCentury | Jun 11, 2019
Company News

June 10 Company Quick Takes: Roche's Spark takeover delayed again; plus Insys, China audits, Novavax and more

...Polivy polatuzumab vedotin-piiq from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) in combination with Treanda...
BioCentury | Mar 1, 2019
Clinical News

FDA concludes Treanda will benefit from Bendeka's exclusivity protection

...or Treanda bendamustine from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) until Dec. 7, 2022, even though Treanda’s...
...period has expired. Bendeka is a ready-to-dilute, 10-minute infusion formulation of bendamustine, an alkylating agent. Treanda...
...request for Orphan exclusivity because Eagle had not shown that Bendeka was clinically superior to Treanda...
BioCentury | Feb 22, 2019
Clinical News

FDA issues handful of new PDUFA dates

...PDUFA date is Aug. 19. FDA will review the antibody-drug conjugate (ADC) in combination with Treanda...
...met the primary endpoint of a greater proportion of patients achieving a complete response vs. Treanda...
BioCentury | Feb 19, 2019
Company News

FDA issues handful of new PDUFA dates

...PDUFA date is Aug. 19. FDA will review the antibody-drug conjugate (ADC) in combination with Treanda...
...met the primary endpoint of a greater proportion of patients achieving a complete response vs. Treanda...
BioCentury | Nov 2, 2018
Clinical News

EC approves AbbVie's Venclexta in combination with Rituxan for CLL

...that Venclexta plus Rituxan met the primary endpoint of improving investigator-assessed progression-free survival (PFS) versus Treanda...
BioCentury | Jun 15, 2018
Clinical News

FDA grants regular approval to Venclexta

...that Venclexta plus Rituxan met the primary endpoint of improving investigator-assessed progression-free survival (PFS) versus Treanda...
BioCentury | Jun 8, 2018
Company News

FDA grants regular approval to Venclexta

...that Venclexta plus Rituxan met the primary endpoint of improving investigator-assessed progression-free survival (PFS) versus Treanda...
BioCentury | May 25, 2018
Clinical News

Genmab's Arzerra misses in Phase III for indolent NHL

...Genmab A/S (CSE:GEN) said Arzerra ofatumumab plus Treanda bendamustine missed the primary endpoint of improving progression-free...
...receive up to eight cycles of Treanda in combination with 12 doses of Arzerra, or Treanda...
BioCentury | May 24, 2018
Clinical News

Genmab's Arzerra misses in Phase III for indolent NHL

...Genmab A/S (CSE:GEN) said Arzerra ofatumumab plus Treanda bendamustine missed the primary endpoint of improving progression-free...
...receive up to eight cycles of Treanda in combination with 12 doses of Arzerra, or Treanda...
Items per page:
1 - 10 of 233